Drug Discovery World

AUGUST 3, 2023

Founded in 2011, the company delivers discovery solutions across medicinal, synthetic, scale-up, process and computational chemistry, as well as DMPK, in vitro biology and in vivo pharmacology. Previous acquisitions were Peak Proteins in April 2022 and SB Drug Discovery in January 2023.

In-Vivo 52

In-Vivo In-Vitro Protein Marketing 52

Roots Analysis

JANUARY 14, 2024

In fact, biologics are anticipated to play a significant role in shaping the pharmaceutical industry and will eventually serve as an integral part of traditional medicines. Overview of Biologics Biologics refer to medicinal / therapeutic products that are either manufactured using living organisms or semi-synthesized from biological sources.

Contract Manufacturing 40

Contract Manufacturing Manufacturing Protein Bacteria 40

The Pharma Data

MARCH 31, 2023

Better understanding of enzymes and their functions would be a boon for research in genomics, chemistry, industrial materials, medicine, pharmaceuticals and more. “Almost every researcher, when working with a new protein sequence, wants to know right away what the protein does. .

Protein 40

Protein Genome Genomics Engineer 40

XTalks

JANUARY 6, 2021

One nanobody in particular, called NIH-CoVnb-112, was shown to be able to prevent COVID-19 infection from the novel coronavirus by targeting both the spike protein on SARS-CoV-2, as well as the angiotensin converting enzyme 2 (ACE2) receptor that it binds to on human cells. The study was led by neuroscientists Thomas J. “TJ”

Antibody 105

Antibody Protein Bacteria In-Vitro 105

The Pharma Data

MAY 31, 2022

About Evrysdi® (risdiplam) Evrysdi is a survival motor neuron 2 (SMN2) splicing modifier designed to treat SMA caused by mutations in chromosome 5q that lead to SMN protein deficiency. Evrysdi is now approved in the US to treat SMA in children and adults of all ages. Jude Children’s Research Hospital.

FDA Approval 52

FDA Approval Protein In-Vitro Medicine 52

The Pharma Data

APRIL 7, 2021

today announced the launch of the Elecsys Anti-p53 immunoassay for the in vitro quantitative determination of anti-p53 antibodies. Beyond breakthrough cancer medicines, Roche also offers a growing number of testing solutions to help physicians diagnose and treat people with cancer. said Thomas Schinecker, CEO Roche Diagnostics.

In-Vitro 52

In-Vitro Antibody Genetics Protein 52

Drug Discovery World

JANUARY 23, 2023

This action sensitised GBM cells to radiotherapy both in vitro and in vivo (in mouse models). “Our research has revealed cladribine as a radiosensitiser for GBM treatment by drug repurposing, which can offer multiple advantages,” says Prof Youn. “As GBM is a WHO grade IV brain tumour with dismal prognosis.

FDA Approval 52

FDA Approval Drugs In-Vivo In-Vitro 52

The Pharma Data

FEBRUARY 25, 2022

“The SARS-CoV-2 vaccines target the spike protein, but this protein is under strong selection pressure and, as we have seen with Omicron, can undergo significant mutations,” said Joyce Jose, assistant professor of biochemistry and molecular biology, Penn State. ” The findings published today (Feb.

FDA Approval 52

FDA Approval Drugs Protein In-Vitro 52

pharmaphorum

NOVEMBER 9, 2022

for the purpose of advancing disease-modifying oral medicines for debilitating chronic neurodegenerative disorders, by enabling investigational new drugs (IND) studies. In ALS , the protein TDP-43 triggers neuroinflammation via activation of the innate immune sensor STING. It has been supporting NRG’s work since 2019.

In-Vitro 52

In-Vitro Bioavailability Medicine Clinical Trials 52

Pharma Mirror

APRIL 21, 2024

With the rapid development of biotechnology and molecular medicine, the introduction of mRNA as a vaccine or therapeutic agent enables the production of almost any desired functional protein/peptide within the human body.

In-Vitro 130

In-Vitro Drugs Genetic Disease RNA 130

Drug Discovery World

APRIL 3, 2023

As the industry moves to reduce the use of animals in research and testing, aptamers also support here, as they are discovered, developed, and manufactured entirely in vitro , removing the need for animals in antibody discovery processes. DDW’s Diana Spencer caught up with co-founder and CEO Dr Arron Tolley.

Antibody 52

Antibody Gene Therapy Gene In-Vitro 52

The Pharma Data

MARCH 25, 2022

This includes about three million people in the EU who are immunocompromised or being treated with immunosuppressive medicines.(1). There is a growing body of evidence from multiple independent in vitro and in vivo (animal model) studies supporting the potential of Evusheld to protect against the BA.1,

Antibody 52

Antibody In-Vivo Medicine Vaccination 52

The Pharma Data

MAY 18, 2021

VENTANA MMR RxDx Panel is a qualitative immunohistochemistry test intended for use in the assessment of mismatch repair (MMR) proteins (MLH1, PMS2, MSH2 and MSH6) in formalin-fixed, paraffin-embedded (FFPE) endometrial carcinoma tissue by light microscopy. Defects in the MMR machinery have been attributed to mutations in the MMR proteins.

FDA Approval 40

FDA Approval DNA Protein In-Vitro 40

The Pharma Data

SEPTEMBER 17, 2020

The test targets antibodies against the spike protein. 1 Specifically, the test targets antibodies which are directed against the particular region of the viral spike protein responsible for binding to the host cell receptor, which is required for the virus to enter the host cell. said Thomas Schinecker, CEO Roche Diagnostics.

Antibody 52

Antibody Vaccination Vaccine In-Vitro 52

The Pharma Data

MAY 27, 2022

Data from the NP30179 study have been submitted for approval to the European Medicines Agency (EMA), and submissions to additional health authorities worldwide, including to the U.S. The pivotal phase II NP30179 expansion study included patients with heavily pre-treated and highly refractory DLBCL, with 58.3% After a median follow-up of 12.6

Antibody 52

Antibody In-Vitro Medicine Engineer 52

pharmaphorum

JANUARY 17, 2023

As it stands, mRNA vaccines and therapeutics can only provide benefits if they can reach the living cells and be processed into protein. Ben Hargreaves speaks to Liberate Bio, a company that is hoping to address the delivery issues that could prevent mRNA, as well as siRNA and ASO therapeutics, from reaching their full potential.

Vaccination 86

Vaccination Vaccine In-Vivo In-Vitro 86

The Pharma Data

MARCH 16, 2022

TIB Molbiol offers a broad range of VirSNiP variant test kits for the detection of key spike protein mutations. The company launched eight RUO VirSNiP test kits for use on LightCycler® and cobas z 480 analyzers, for the detection of key spike protein mutations present in the novel B.1.1.529 3 and Delta.

In-Vitro 52

In-Vitro Genotype Reagent Protein 52

The Pharma Data

MARCH 22, 2023

About the Elecsys ® Amyloid Plasma Panel The Elecsys Amyloid Plasma Panel measures phosphorylated Tau (pTau) 181 protein assay and apolipoprotein (APOE) E4 assay in human blood plasma. Today, the company’s Alzheimer’s portfolio spans investigational medicines for different targets, types and stages of the disease.

In-Vitro 40

In-Vitro Medicine Development Branding 40

The Pharma Data

DECEMBER 9, 2020

Li is a prominent neuroscientist and former professor at Johns Hopkins Medicine. The company plans to do this by developing drugs that eliminate protein aggregation by either reducing the production of toxic proteins or removing them after the fact through autophagy. which will remain a key shareholder. SciNeuro Pharmaceuticals.

Marketing 52

Marketing In-Vivo Protein In-Vitro 52

The Pharma Data

AUGUST 6, 2020

Safety for the Tecentriq combination appeared to be consistent with the known safety profile of the individual medicines, and no new safety signals were identified. This includes studies evaluating Tecentriq both alone and in combination with other medicines. Roche’s Chief Medical Officer and Head of Global Product Development.

Medicine 52

Medicine In-Vitro Protein Antibody 52

The Pharma Data

SEPTEMBER 1, 2020

Antigen test reliably and quickly triages people suspected of SARS-CoV-2, with results ready in 15 minutes, allowing informed treatment decisions. Antigen test accurately screens individuals with known exposure to infected SARS-CoV-2 patients, providing fast answers regarding their infection status. Food and Drug Administration (FDA).

In-Vitro 52

In-Vitro Antibody Medicine Clinical Trials 52

The Pharma Data

DECEMBER 20, 2020

Elizabeth’s Medical Center and associate professor of Urology at Tufts University School of Medicine, said at the time, “The results of the EMPOUR study over the 52-week period demonstrated the sustained benefits of fibegron. The drug is a once-daily, beta-3 adrenergic agonist. and Europe, including Russia.

In-Vitro 52

In-Vitro FDA Approval Manufacturing Drugs 52

The Pharma Data

SEPTEMBER 18, 2020

Recommendation is based on the results of the IMbrave150 study, in which the Tecentriq combination improved overall survival and progression-free survival compared with the previous standard of care. Chief Medical Officer and Head of Global Product Development. Chief Medical Officer and Head of Global Product Development.

Medicine 52

Medicine HR In-Vitro Protein 52

The Pharma Data

APRIL 23, 2021

These results were published in the New England Journal of Medicine in August 2020. Roche announces positive CHMP opinion for Venclyxto-based combinations in certain patients with acute myeloid leukaemia. The VIALE-A study showed Venclyxto plus azacitidine significantly improved overall survival compared to azacitidine alone.

Medicine 40

Medicine In-Vitro Antibody Branding 40

The Pharma Data

NOVEMBER 11, 2020

ADDS IN VITRO PHARMACOLOGY AND EXPANDS PROTEIN SCIENCES. CREATES UNIQUE CO-LOCATED, FULLY-INTEGRATED, HIGH-CAPACITY R&D CENTRE. CREATES CENTRE OF EXCELLENCE FOR STRUCTURE-BASED DRUG DESIGN. ” About Dorothy Crowfoot Hodgkin Dorothy Hodgkin (née Crowfoot) was born in Cairo in 1910.

In-Vitro 40

In-Vitro Insulin Development Containment 40

Drug Discovery World

OCTOBER 4, 2022

There’s no question that cell and gene therapies have emerged as some of the most promising and innovative medicines on the market. . billion in 2020, according to the Alliance for Regenerative Medicine’s (ARM’s): Disrupting the Status Quo report. Cell and gene therapies. In 2021, levels of investment hit an all-time high at $22.7

Gene Therapy 52

Gene Therapy Drugs Gene Manufacturing 52

The Pharma Data

MAY 17, 2023

BTK, also known as tyrosine-protein kinase BTK, is an enzyme that regulates B-cell development and activation and is also involved in the activation of innate immune system myeloid lineage cells, such as macrophages and microglia. Roche’s Chief Medical Officer and Head of Global Product Development.

FDA Approval 40

FDA Approval In-Vitro Trials Clinical Trials 40

The Pharma Data

MARCH 22, 2022

Additionally, Pfizer has signed a voluntary license agreement with the Medicines Patent Pool (MPP) for its oral treatment to help expand access, pending country regulatory authorization or approval, in 95 low- and middle-income countries that account for approximately 53% of the world’s population.

In-Vitro 52

In-Vitro Contract Manufacturing Manufacturing Production 52

XTalks

AUGUST 12, 2020

Studies have identified the presence of two types of HIV-infected CD4+ T cells: ‘Transcriptionally inactive’ cells that do not typically produce viral RNA or viral proteins. This may help explain why HIV is adequately controlled, but not eradicated, with current treatments. The research study was published in Cell Reports.

RNA 52

RNA Protein DNA In-Vivo 52

Drug Discovery World

JANUARY 17, 2024

Brett Swansiger, Chief Commercial Officer at ANGLE discusses the importance of liquid biopsies in precision medicine trials for cancer. As such there is a need to develop fast and accurate methods to assess drug safety and efficacy, facilitating early success or failure.

Medicine 59

Medicine DNA Genome Genomics 59

Pfizer

AUGUST 15, 2022

Current variants of concern can be resistant to treatments that work by binding to the spike protein found on the surface of the SARS-CoV-2 virus. Nirmatrelvir has shown consistent in vitro antiviral activity against the following variants: Alpha, Beta, Delta, Gamma, Lambda, Mu, and Omicron BA.1

Drugs 99

Drugs Vaccination Vaccine In-Vitro 99

The Pharma Data

APRIL 27, 2021

The FDA’s Accelerated Approval Program allows for conditional approval of a medicine that fills an unmet medical need for a serious condition, with specific postmarketing requirements (PMRs) to confirm the clinical benefit and convert to regular approval. Roche’s Chief Medical Officer and Head of Global Product Development.

Medicine 40

Medicine In-Vitro Antibody Development 40

The Pharma Data

AUGUST 18, 2020

We are excited about the potential for one medicine to serve both as a treatment for those infected as well as protection for people exposed to the virus. REGN-COV2 is Regeneron’s two-antibody combination currently in late-stage clinical trials for the treatment and prevention of COVID-19 infection. and around the world. and around the world.

Antibody 52

Antibody Clinical Trials Clinical Trials Manufacturing 52

The Pharma Data

JULY 23, 2021

The antibody combination was granted a Special Approval Pathway under article 14-3 of the Pharmaceuticals and Medical Devices Act. “Ronapreve has been shown to improve survival in high-risk, non-hospitalised COVID-19 patients by reducing the risk of hospitalisation and death. About Ronapreve (casirivimab and imdevimab).

Antibody 52

Antibody Medicine Production In-Vitro 52

The Pharma Data

MAY 18, 2021

The FDA’s Accelerated Approval Program allows conditional approval of a medicine that fills an unmet medical need for a serious condition, with specific postmarketing requirements (PMRs) to confirm the clinical benefit and convert to regular approval. Roche’s Chief Medical Officer and Head of Global Product Development.

Medicine 52

Medicine Containment In-Vitro Development 52

Pfizer

JANUARY 27, 2023

Current variants of concern can be resistant to treatments that work by binding to the spike protein found on the surface of the SARS-CoV-2 virus. PAXLOVID is currently approved or authorized for conditional or emergency use in more than 70 countries to treat COVID-19.

Marketing 75

Marketing Production Drugs Licensing 75

Pharmaceutical Technology

JANUARY 4, 2023

The Gremlin1 protein was found to promote lineage plasticity while driving castration resistance in prostate cancer. A synergistic activity was also observed between the anti-Gremlin1 antibody and enzalutamide against castration-resistant prostate cancer models derived from patients in vitro and in vivo.

Antibody 242

Antibody In-Vivo In-Vitro Protein 242